

Otezla® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)								
Member Name:			Provider Name:								
Insurance ID#:			NPI#:		Specialty:						
Date of Birth:			Office Phone:								
Street Address:			Office Fax:								
City:	State:	Zip:	Office Street Address:								
Phone:			City:	State:	Zip:						
Medication Information (required)											
Medication Name:			Strength:		Dosage Form:						
<input type="checkbox"/> Check if requesting brand			Directions for Use:								
<input type="checkbox"/> Check if request is for continuation of therapy											
Clinical Information (required)											
Select the diagnosis below: <input type="checkbox"/> Active psoriatic arthritis <input type="checkbox"/> Moderate to severe chronic plaque psoriasis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____											
Clinical Information: Has the patient tried and failed at least 3 months of methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient receiving Otezla in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept)]? <input type="checkbox"/> Yes <input type="checkbox"/> No Select if Otezla is prescribed by one of the following specialists: <input type="checkbox"/> Dermatologist <input type="checkbox"/> Rheumatologist											
For active psoriatic arthritis, also answer the following: Is the patient receiving Otezla in combination with a Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib XR)]? <input type="checkbox"/> Yes <input type="checkbox"/> No											
For moderate to severe chronic plaque psoriasis, also answer the following: Select if the patient has had trial and failure of topical therapy for at least three (3) months with the following: <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; padding: 5px;"><input type="checkbox"/> Anthralin Coal tar</td> <td style="width: 50%; padding: 5px;"><input type="checkbox"/> Tazarotene</td> </tr> <tr> <td style="padding: 5px;"><input type="checkbox"/> Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)</td> <td style="padding: 5px;"><input type="checkbox"/> Vitamin D analogs (e.g., calcitriol, calcipotriene)</td> </tr> <tr> <td style="padding: 5px;"><input type="checkbox"/> Coal tar</td> <td style="padding: 5px;"><input type="checkbox"/> Corticosteroids (e.g., betamethasone, clobetasol, desonide)</td> </tr> </table>						<input type="checkbox"/> Anthralin Coal tar	<input type="checkbox"/> Tazarotene	<input type="checkbox"/> Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)	<input type="checkbox"/> Vitamin D analogs (e.g., calcitriol, calcipotriene)	<input type="checkbox"/> Coal tar	<input type="checkbox"/> Corticosteroids (e.g., betamethasone, clobetasol, desonide)
<input type="checkbox"/> Anthralin Coal tar	<input type="checkbox"/> Tazarotene										
<input type="checkbox"/> Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)	<input type="checkbox"/> Vitamin D analogs (e.g., calcitriol, calcipotriene)										
<input type="checkbox"/> Coal tar	<input type="checkbox"/> Corticosteroids (e.g., betamethasone, clobetasol, desonide)										
Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. *Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*											
Prescriber Signature: _____			Date: _____								

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-800-711-4555.
 This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
 Office use only: Otezla_Optima_2018Feb-W